Version number: 03

SAFETY DATA SHEET



Section 1 - Identification

Product identifier Mavacoxib Tablets

Other means of identification

Synonyms TROCOXIL

Recommended use of the chemical and restrictions on use

Recommended use Veterinary product used as non-steroidal, anti-inflammatory drug (nsaid)

Restrictions on use Not for human use

Details of manufacturer or importer

Company Name (AU) Zoetis Australia Pty Ltd

ABN 94 156 476 425 Level 6, 5 Rider Boulevard

Rhodes NSW 2138 AUSTRALIA

Tel 1800 814 883 **Fax** (02) 8876 0444

Email productsupport.au@zoetis.com

Emergency Phone 1800 814 883 (all hours)

Police and Fire Brigade Dial 000

If ineffective Dial Poisons Information Centre (13 1126 from anywhere in Australia)

Section 2 - Hazard(s) identification

Classification of the hazardous chemical

Physical hazards Not classified.

Health hazards Specific target organ toxicity, repeated Category 2

exposure

Environmental hazards Hazardous to the aquatic environment, acute Category 3

hazard

Hazardous to the aquatic environment, Category 3

long-term hazard

Label elements, including precautionary statements

Hazard symbol(s)



Health I hazard

Exclamation mark

Signal word Warning

Hazard statement(s) May cause damage to organs through prolonged or repeated exposure. (Gastro-intestinal tract.

Kidneys.) Harmful to aquatic life with long lasting effects.

Precautionary statement(s)

Prevention Do not breathe dust/fume/gas/mist/vapors/spray. Avoid release to the environment.

Response Get medical advice/attention if you feel unwell.

Storage Store away from incompatible materials.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Supplemental information None.

Other hazards which do not

result in classification

None known.

Section 3 - Composition and information on ingredients

Mixture

531-ZA

Identity of chemical ingredients	CAS number and other unique identifiers	Concentration of ingredients (%)
Sugar	57-50-1	< 60
Microcrystalline cellulose	9004-34-6	< 30
Mavacoxib	170569-88-7	5
Magnesium Stearate	557-04-0	1 - < 3
Sodium lauryl sulfate	151-21-3	1 - < 3

Composition comments

Other components below reportable levels

Section 4 - First aid measures

Description of necessary first aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Wash off with soap and water, Get medical advice/attention if you feel unwell. Get medical Skin contact

attention if irritation develops and persists. Wash contaminated clothing before reuse.

Immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if Eye contact

present and easy to do. Continue rinsing. Get medical attention if irritation develops and persists.

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Personal protection for first-aid

responders

Ingestion

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance. You should call The Poisons Information Centre if you feel that you may have been poisoned, burned or irritated by this product. The number is 13 1126 from anywhere in Australia (0800 764 766 in New Zealand) and is available at all times. Have this SDS with you when you call.

Symptoms caused by exposure

Prolonged exposure may cause chronic effects. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Ingestion of this material may cause effects similar to those seen in clinical use including changes in blood chemistry, gastrointestinal system and kidney effects, diarrhea and vomiting.

Medical attention and special

treatment

Provide general supportive measures and treat symptomatically. Symptoms may be delayed.

Section 5 - Firefighting measures

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for fire

fighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Hazchem code

General fire hazards

No unusual fire or explosion hazards noted.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

Extinguishing media

Suitable extinguishing

media

Water fog. Alcohol resistant foam. Powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

Do not use water jet as an extinguisher, as this will spread the fire.

Section 6 - Accidental release measures

Personal precautions, protective equipment and emergency procedures

None.

For non-emergency

personnel

Keep unnecessary personnel away.

For emergency responders

Keep unnecessary personnel away. Avoid dust formation. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. Use personal protection

recommended in Section 8 of the SDS.

Environmental precautions

Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.

Material name: Mavacoxib Tablets SDS AUSTRALIA 531-ZA 2/9 Methods and materials for containment and cleaning up

Prevent product from entering drains.

Large Spills: Stop the flow of material, if this is without risk. Clean surface thoroughly to remove residual contamination.

Small Spills: Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Section 7 - Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. When using, do not eat, drink or smoke. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Avoid release to the environment. Wash contaminated clothing before reuse. Observe good industrial hygiene practices. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Conditions for safe storage, including any incompatibilities

Store in tightly closed container. Store away from incompatible materials (see Section 10 of the

Section 8 - Exposure controls and personal protection

Control parameters

Zoetis

Follow standard monitoring procedures.

Occupational exposure limits

Components	Туре	Value	
Mavacoxib (CAS 170569-88-7)	TWA	0.001 mg/m³	
Sodium lauryl sulfate (CAS 151-21-3)	TWA	0.3 mg/m3	
Australia. National Workplace OE	Ls (Workplace Exposure Star	ndards for Airborne Contamir	ants, Appendix A)
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	10 mg/m3	Inhalable dust.
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	Inhalable fibers.
Sugar (CAS 57-50-1)	TWA	10 mg/m3	Inhalable dust.
US. ACGIH Threshold Limit Value	S		
Components	Туре	Value	Form
Magnesium Stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable fraction.
		10 mg/m3	Inhalable fraction.
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	
Sugar (CAS 57-50-1)	TWA	10 mg/m3	
UK. EH40 Workplace Exposure Li	mits (WELs)		
Components	Туре	Value	Form
Microcrystalline cellulose (CAS 9004-34-6)	STEL	20 mg/m3	Inhalable dust.
	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Inhalable dust.
Sugar (CAS 57-50-1)	STEL	20 mg/m3	
	TWA	10 mg/m3	

Germany. DFG MAK List (advisory OELs). Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (DFG)

Components	Туре	Value	Form
Microcrystalline cellulose (CAS 9004-34-6)	TWA	4 mg/m3	Inhalable dust.
Sugar (CAS 57-50-1)	TWA	4 mg/m3	Inhalable dust.

Biological limit values No biological exposure limits noted for the ingredient(s).

Material name: Mavacoxib Tablets SDS AUSTRALIA

Appropriate engineering

controls

Engineering controls should be used as the primary means to control exposures. General room

ventilation is adequate unless the process generates dust, mist or aerosols.

Individual protection measures, for example personal protective equipment (PPE)

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Wear appropriate chemical resistant gloves.

Other Wear suitable protective clothing. Impervious protective clothing is recommended if skin contact

with drug product is possible and for bulk processing operations.

Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment. Respiratory protection

should be provided in instances where exposure to dust, mists, aerosols or vapors are likely. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a

protection factor sufficient to control exposures to below the OEL.

Thermal hazards Not applicable.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

Section 9 - Physical and chemical properties

Odor Not available.
Odor threshold Not available.
pH Not available.

Melting point/freezing point 311 °F (155 °C) estimated

Initial boiling point and boiling

range

Not available.

Flash pointNot available.Evaporation rateNot available.Flammability (solid, gas)Not available.

Upper/lower flammability or explosive limits

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Not available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other physical and chemical parameters

Explosive properties Not explosive.

Oxidizing properties Not oxidizing.

Tablet

AppearanceTabletPhysical stateSolid.FormSolid.ColorBrown.

Section 10 - Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Strong oxidizing agents. Fluorine.

Material name: Mavacoxib Tablets SDS AUSTRALIA

Hazardous decomposition

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

products

Section 11 - Toxicological information

Information on possible routes of exposure

Under normal conditions of intended use, this material is not expected to be an Inhalation

inhalation hazard.

No adverse effects due to skin contact are expected. Skin contact

Sodium lauryl sulfate Species: Rabbit

Severity: Mild Moderate

Microcrystalline cellulose Species: Rabbit

Severity: Non-irritating

Mavacoxib Species: Rabbit

Severity: Slight

Eve contact Direct contact with eyes may cause temporary irritation.

Mavacoxib Species: Rabbit

Severity: Minimal

Sodium lauryl sulfate Species: Rabbit

Severity: Moderate

Microcrystalline cellulose Species: Rabbit

Severity: Non-irritating

Expected to be a low ingestion hazard. Ingestion

Prolonged exposure may cause chronic effects. Other nonsteroidal anti-inflammatorv Symptoms related to exposure

drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Ingestion of this material may cause effects similar to those seen in clinical use including changes in blood chemistry, Gastrointestinal and kidney effects, diarrhea and

vomiting.

Expected to be a low hazard for usual industrial or commercial handling by trained Acute toxicity

personnel.

Test Results Components **Species**

Magnesium Stearate (CAS 557-04-0)

Acute

Oral

LD50 Rat 1092

Mavacoxib (CAS 170569-88-7)

Acute

Dermal

LD50 Rat > 2000 ma/ka

Oral

LD Rat 500 mg/kg (Minimum Lethal Dose)

Chronic

Oral

NOAEL Dog 20 mg/kg, 6 months (No effects at

maximum dose, 20 mg/kg/day for 28 days)

Subacute

Oral

LOAEL 5 mg/kg/day, 1 months (Gastrointestinal Rat

system, Kidney)

Microcrystalline cellulose (CAS 9004-34-6)

Acute

Dermal

LD50 Rabbit > 2000 mg/kg

Material name: Mavacoxib Tablets SDS AUSTRALIA 531-ZA

Components **Species Test Results** Oral LD50 > 5000 mg/kg Rat Sodium lauryl sulfate (CAS 151-21-3) Acute Oral LD50 Rat 1288 mg/kg Sugar (CAS 57-50-1) Acute Oral LD50 Mouse 14000 mg/kg Rat 29700 mg/kg Based on available data, the classification criteria are not met. Prolonged skin contact may cause Skin corrosion/irritation temporary irritation. Corrosivity Mavacoxib Result: Irritant Species: Rabbit Severity: Slight Based on available data, the classification criteria are not met. Direct contact with eyes may cause Serious eye damage/irritation temporary irritation. **Eye Contact** Mavacoxib Species: Rabbit Severity: Minimal Sodium lauryl sulfate Species: Rabbit Severity: Moderate Microcrystalline cellulose Species: Rabbit Severity: Non-irritating Respiratory or skin sensitization Respiratory sensitization Not a respiratory sensitizer. Skin sensitization This product is not expected to cause skin sensitization. Skin sensitization Species: Guinea Pig Mavacoxib Severity: Negative Sodium lauryl sulfate Species: Guinea Pig Severity: Negative Mavacoxib Species: Mouse

Severity: Negative

Sodium lauryl sulfate Species: Mouse

Severity: Negative

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

Mavacoxib Bacterial Mutagenicity (Ames)

Result: Negative

Species: Salmonella, E. coli

Sodium lauryl sulfate Bacterial Mutagenicity (Ames)

Result: Negative Species: Salmonella

Mavacoxib In Vitro Chromosome Aberration

Result: Negative

Species: Human Lymphocytes

Material name: Mavacoxib Tablets SDS AUSTRALIA

Mutagenicity

Mavacoxib In Vivo Micronucleus Result: Negative

Species: Rat

Carcinogenicity Due to partial or complete lack of data the classification is not possible. This product is

not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

ACGIH Carcinogens

Magnesium Stearate (CAS 557-04-0) A4 Not classifiable as a human carcinogen. Sugar (CAS 57-50-1) A4 Not classifiable as a human carcinogen.

This product is not expected to cause reproductive or developmental effects. Reproductive toxicity

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

May cause damage to organs through prolonged or repeated exposure. (

Gastrointestinal tract. Kidneys.)

Aspiration hazard Not an aspiration hazard.

May cause damage to organs through prolonged or repeated exposure. Chronic effects

Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late Other information

fetal development, and lactation.

Section 12 - Ecological information

Ecotoxicity Avoid release to the environment, Harmful to aquatic life with long lasting effects.

Components		Species	Test Results
Mavacoxib (CAS 170569-8	38-7)		
	EbC50	Skeletonema costatum (Marine Diatom)	3.9 mg/L, 96 Hours
	EC50	Activated sludge	> 100 mg/L, 3 Hours
	LC50	Scopthalamus maximus (Turbot)	> 3.2 mg/L, 96 Hours
		Tisbe battagliai (Marine Copepod)	4 mg/L, 48 Hours
Sodium lauryl sulfate (CAS	S 151 - 21-3)		
Aquatic			
Fish	LC50	Oncorhynchus mykiss (Rainbow Trout)	3.6 mg/L, 96 Hours
Acute			
Crustacea	EC50	Water flea (Daphnia obtusa)	9.2 - 10.4 mg/l, 48 hours
Fish	LC50	Carp (Cyprinus carpio)	1.31 mg/l, 96 hours

Persistence and degradability

No data available for this product.

Bioaccumulative potential

No data available.

Mobility in soil

No data available for this product.

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

Section 13 - Disposal considerations

Avoid release to the environment. Considering the relevant known environmental and human **Disposal methods**

> health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international

regulations.

Dispose of in accordance with local regulations. Empty containers or liners may retain some Residual waste

product residues. This material and its container must be disposed of in a safe manner.

Since emptied containers may retain product residue, follow label warnings even after container is Contaminated packaging

emptied.

Section 14 - Transport information

ADG

Not regulated as dangerous goods.

Material name: Mavacoxib Tablets SDS AUSTRALIA

RID

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

Section 15 - Regulatory information

Safety, health and environmental regulations

National regulations

This Safety Data Sheet was prepared in accordance with Australia Model Code of Practice for the preparation of Safety Data Sheets for Hazardous Chemicals.

Poison Schedule (Product): Schedule 4

APVMA No: 64466	TROCOXIL 6MG CHEWABLE TABLETS FOR DOGS
APVMA No: 64465	TROCOXIL 20MG CHEWABLE TABLETS FOR DOGS
APVMA No: 64464	TROCOXIL 30MG CHEWABLE TABLETS FOR DOGS
APVMA No: 64463	TROCOXIL 75MG CHEWABLE TABLETS FOR DOGS
APVMA No: 64462	TROCOXIL 95MG CHEWABLE TABLETS FOR DOGS

Australia Medicines & Poisons Appendix E

Sodium lauryl sulfate (CAS 151-21-3)

Australia Medicines & Poisons Schedule 4

Mavacoxib (CAS 170569-88-7)

High Volume Industrial Chemicals (HVIC)

Not listed.

Importation of Ozone Depleting Substances (Customs(Prohibited imports) Regulations 1956, Schedule 10, as amended)

National Pollutant Inventory (NPI) substance reporting list

Microcrystalline cellulose (CAS 9004-34-6) 2000 TONNES/YR Threshold Category: 2B 400 TONNES/YR Threshold Category: 2A Sugar (CAS 57-50-1)

2000 TONNES/YR Threshold Category: 2B 400 TONNES/YR Threshold Category: 2A

Prohibited Carcinogenic Substances

Not regulated.

Prohibited Substances (National Model Regulation for the control of Workplace Hazardous Substances, Schedule 2 NOHSC:1005 (1994) as amended)

Not listed.

Restricted Carcinogenic Substances

Not regulated.

Restricted Importation of Organochlorine Chemicals (Customs(Prohibited Imports) Regulations 1956, Schedule 9)

Not listed.

International regulations

Stockholm Convention

Not applicable.

Rotterdam Convention

Not applicable.

Kyoto protocol

Not applicable.

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

Material name: Mavacoxib Tablets SDS AUSTRALIA 531-ZA

International Inventories

Country(s) or region	Inventory name On inventory (y	/es/no)*
Australia	Australian Inventory of Industrial Chemicals (AICIS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
Taiwan	Taiwan Chemical Substance Inventory (TCSI)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No
* A UN/U !!!4 4 4U		

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

Section 16 - Any other relevant information

13 February 2014 Issue date 23 February 2023 **Revision date**

Key abbreviations or acronyms

used Disclaimer AICIS: Australian Inventory of Industrial Chemicals.

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The

information in the sheet was written based on the best knowledge and experience currently available.

Revision information This document has undergone significant changes and should be reviewed in its entirety.

SDS AUSTRALIA 531-ZA